Top Profitable and Promising Biotechnology Investments

Investing in the biotechnology industry can offer substantial rewards but also involves significant risk. Historically, many biotech stocks face challenges gaining market acceptance for their innovative products. However, recent tax reforms reducing corporate taxes from 35% to 21% are encouraging mergers and acquisitions, often resulting in upward share price movement. Several biotech firms, such as those listed below, have demonstrated consistent growth and are expected to continue expanding in the upcoming months.

One notable example is CRISPR Therapeutics AG, listed as CRSP on NASDAQ. This Swiss-based gene editing company has experienced over 213% annual growth in recent years and shows promising recovery from losses. Similarly, Aeglea Biotherapeutics Inc., founded in Texas, has achieved nearly 89% gains this year with a focus on enzyme research for rare diseases and cancer therapies that suggest manageable loss forecasts.

CRISPR Therapeutics AG - With rapid expansion, this biotech firm has become a leader in gene editing, offering significant growth potential and minimal loss projections for 2019.

Aeglea Biotherapeutics Inc. - Specializing in enzyme-based treatments, this Texas-based company has posted high returns and expects stable future losses, making it a strong candidate for investment.

Athersys, Inc. - Recognized on NASDAQ as ATHX, this pioneer in regenerative medicine has seen considerable growth, boasting over 426% increase in sales in 2018 and solid weekly returns, despite some higher loss estimates for upcoming years.

Ligand Pharmaceuticals Inc. - Based in San Diego and traded as LGND, this company excels in licensing key medications, with impressive revenue growth and moderate projected losses, indicating resilient performance.